Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Lawrence HR., Vicker N., Allan GM., Smith A., Mahon MF., Tutill HJ., Purohit A., Reed MJ., Potter BV.
Structure-based drug design using the crystal structure of human 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) led to the discovery of novel, selective, and the most potent inhibitors of 17beta-HSD1 reported to date. Compounds 1 and 2 contain a side chain with an m-pyridylmethyl-amide functionality extended from the 16beta position of a steroid scaffold. A mode of binding is proposed for these inhibitors, and 2 is a steroid-based 17beta-HSD1 inhibitor with the potential for further development.